Department of Obstetrics and Gynaecology, Queen Elizabeth Hospital, Hong Kong SAR, China.
Department of Obstetrics and Gynaecology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia.
Genes (Basel). 2023 May 30;14(6):1203. doi: 10.3390/genes14061203.
Skeletal dysplasias are a group of diseases characterized by bone and joint abnormalities, which can be detected during prenatal ultrasound. Next-generation sequencing has rapidly revolutionized molecular diagnostic approaches in fetuses with structural anomalies. This review studies the additional diagnostic yield of prenatal exome sequencing in fetuses with prenatal sonographic features of skeletal dysplasias. This was a systematic review by searching PubMed for studies published between 2013 and July 2022 that identified the diagnostic yield of exome sequencing after normal karyotype or chromosomal microarray analysis (CMA) for cases with suspected fetal skeletal dysplasias based on prenatal ultrasound. We identified 10 out of 85 studies representing 226 fetuses. The pooled additional diagnostic yield was 69.0%. The majority of the molecular diagnoses involved de novo variants (72%), while 8.7% of cases were due to inherited variants. The incremental diagnostic yield of exome sequencing over CMA was 67.4% for isolated short long bones and 77.2% for non-isolated cases. Among phenotypic subgroup analyses, features with the highest additional diagnostic yield were an abnormal skull (83.3%) and a small chest (82.5%). Prenatal exome sequencing should be considered for cases with suspected fetal skeletal dysplasias with or without a negative karyotype or CMA results. Certain sonographic features, including an abnormal skull and small chest, may indicate a potentially higher diagnostic yield.
骨骼发育不良是一组以骨骼和关节异常为特征的疾病,这些异常可以在产前超声检查中发现。下一代测序技术迅速改变了结构异常胎儿的分子诊断方法。本综述研究了产前外显子组测序在具有骨骼发育不良产前超声特征的胎儿中的额外诊断收益。这是一项系统综述,通过在 PubMed 上搜索 2013 年至 2022 年 7 月期间发表的研究,这些研究根据产前超声确定了在正常核型或染色体微阵列分析(CMA)后疑似胎儿骨骼发育不良病例的外显子组测序的诊断收益。我们从 85 项研究中确定了 10 项,代表 226 例胎儿。汇总的额外诊断收益为 69.0%。大多数分子诊断涉及新生变异(72%),而 8.7%的病例是由于遗传变异。外显子组测序对 CMA 的增量诊断收益分别为孤立短长骨的 67.4%和非孤立病例的 77.2%。在表型亚组分析中,具有最高额外诊断收益的特征是异常颅骨(83.3%)和小胸部(82.5%)。对于疑似胎儿骨骼发育不良的病例,无论核型或 CMA 结果是否为阴性,都应考虑进行产前外显子组测序。某些超声特征,包括异常颅骨和小胸部,可能表明潜在的更高诊断收益。